- Home
- ASPC vs ACHV Comparison
ASPC vs ACHV Comparison
Compare ASPC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPC
- ACHV
- Stock Information
- Founded
- ASPC 2024
- ACHV N/A
- Country
- ASPC Hong Kong
- ACHV Canada
- Employees
- ASPC N/A
- ACHV N/A
- Industry
- ASPC
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ASPC
- ACHV Health Care
- Exchange
- ASPC Nasdaq
- ACHV Nasdaq
- Market Cap
- ASPC 80.9M
- ACHV 72.5M
- IPO Year
- ASPC 2024
- ACHV N/A
- Fundamental
- Price
- ASPC $10.14
- ACHV $2.64
- Analyst Decision
- ASPC
- ACHV Strong Buy
- Analyst Count
- ASPC 0
- ACHV 3
- Target Price
- ASPC N/A
- ACHV $14.33
- AVG Volume (30 Days)
- ASPC 9.6K
- ACHV 202.1K
- Earning Date
- ASPC 01-01-0001
- ACHV 05-16-2025
- Dividend Yield
- ASPC N/A
- ACHV N/A
- EPS Growth
- ASPC N/A
- ACHV N/A
- EPS
- ASPC N/A
- ACHV N/A
- Revenue
- ASPC N/A
- ACHV N/A
- Revenue This Year
- ASPC N/A
- ACHV N/A
- Revenue Next Year
- ASPC N/A
- ACHV N/A
- P/E Ratio
- ASPC N/A
- ACHV N/A
- Revenue Growth
- ASPC N/A
- ACHV N/A
- 52 Week Low
- ASPC $9.95
- ACHV $1.84
- 52 Week High
- ASPC $10.51
- ACHV $5.59
- Technical
- Relative Strength Index (RSI)
- ASPC N/A
- ACHV 56.59
- Support Level
- ASPC N/A
- ACHV $2.32
- Resistance Level
- ASPC N/A
- ACHV $2.63
- Average True Range (ATR)
- ASPC 0.00
- ACHV 0.18
- MACD
- ASPC 0.00
- ACHV 0.07
- Stochastic Oscillator
- ASPC 0.00
- ACHV 93.26
About ASPC A SPAC III Acquisition Corp. Class A Ordinary Shares
A SPAC III Acquisition Corp is a blank check company.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.